This invention relates to methods and compositions for treating central nervous system (CNS) disorders with cognitive impairment. In particular it relates to the use of inhibitors of synaptic vesicle glycoprotein 2A (SV2A) alone or in combination with valproate in treating central nervous system (CNS) disorders with cognitive impairment in a subject in need or at risk thereof including without limitation subjects having or at risk for age related cognitive impairment Mild Cognitive Impairment (MCI) amnestic MCI (aMCl ) Age Associated Memory Impairment (AAMI) Age Related Cognitive Decline (ARCD) dementia Alzheimer s Disease(AD) prodromal AD post traumatic stress disorder (PTSD) schizophrenia amyotrphic lateral sclerosis and cancer therapy related cognitive impairment.
